Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 3, 2010, Pages 195-204

  Bhatt, Valkal ^a,b   Vendrell, Nancy ^a   Nau, Karen ^a   Crumb, Deborah ^a   Roy, Vivek ^a  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

bone marrow transplant; mucositis; oral care protocol

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BUSULFAN; CALCIUM PHOSPHATE; CARMUSTINE; CHLORHEXIDINE GLUCONATE; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; MESNA; MOUTHWASH; NARCOTIC ANALGESIC AGENT; PALIFERMIN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOTHERAPY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LENGTH OF STAY; MALE; MOUTH HYGIENE; MOUTH PAIN; NEUTROPENIA; NURSING STAFF; NUTRITIONAL STATUS; PARENTERAL NUTRITION; PHYSICIAN; PRIORITY JOURNAL; STANDARDIZATION; STOMATITIS; TOOTH BRUSHING; TOTAL PARENTERAL NUTRITION; WHOLE BODY RADIATION; XEROSTOMIA;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; CLINICAL PROTOCOLS; CRYOTHERAPY; FEMALE; FIBROBLAST GROWTH FACTOR 7; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MOUTHWASHES; MUCOSITIS; PILOT PROJECTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STANDARD OF CARE;

EID: 77956261466     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209348721     Document Type: Article

References (21)

1. Goldberg S. Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/prophylaxis strategies. Support Care Cancer 2004 ; 12: 526-530.
2. Woo S. -B. A longitudinal study of oral ulcerative mucositis in bone marrow transplant patients. Cancer 1993 ; 72 (5). 1612-1617.
3. Lalla R. Treatment of mucositis, including new medications. Cancer 2006 ; 12: 348-354.
4. Rubenstein EB, Peterson DE, Schubert M. et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004 ; 100 (9). 2026-2046.
5. McGuire D. Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer 2003 ; 11: 435-441.
6. Sonis ST Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998 ; 34 (1). 39-43.
7. Ferretti GA, Ash RC, Brown RT et al. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transpl 1988 ; 3 (5). 483-493.
8. Raether D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatr Dent 1989 ; 11 (1). 37-42.
9. Ezzone S. Survey of oral hygiene regimens among bone marrow transplant centers. Oncol Nurs Forum 1993 ; 20 (9). 1375-1381.
10. Beck S. Impact of a systematic oral care protocol on stomatitis after chemotherapy. Cancer Nurs 1979 ; 2 (3). 185-199.
11. Lorenz K. Effect of two new chlorhexidine mouth rinses on the development of dental plaque, gingivitis and discoloration. A randomized, investigator-blind, placebo controlled 3 week experimental gingivitis study J Clin Periodontol 2006 ; 33 (8). 561-567.
12. Papas AS, Clark RE, Martuscelli G., O'Loughlin KT, Johansen E., Miller KB A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopooietic stem cell transplantation. Bone Marrow Transpl 2003 ; 31: 705-712.
13. Potting CMJ. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Euro J Crit Care 2006 ; 15: 431-439.
14. Palifermin (Kepivance®). Mayo Clinic Pharmacy and Therapeutics Committee Criteria for Use. Approved November 2005. Available at: http://mcjweb.mayo.edu/pt-committee/Documents/criteria%20for%20use/ Palifermin%20cfu.pdf (accessed September 2008 ).
15. Lilleby K., Garcia P., Gooley T., McDonnnell P., Taber R., Holmberg L. et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood cell transplantation. Bone Marrow transpl 2006 ; 37: 1031-1035.
16. Woo SB, Matin K. Off-site dental evaluation program for prospective bone marrow transplant recipients. J Am Dental Assoc 1997 ; 128: 189-193.
17. Peterson D. Mouth pain and discomfort: All you need to know about mucositis, Cancer Care Connect, 2005. Available at: http://www.cancercare.org. (accessed September 2008 ).
18. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3. Available at: http://www.fda.gov/cder/cancer/toxicityframe. htm. (accessed September 4 2008 ).
19. Caphosol Patient Administration guide. Available at: http://www.caphosol. com/assets/pdf/patients/CaphosolPatientInstructionSheet (accessed September 2008 ).
20. Dodd M. Randomized clinical trial of the effectiveness of three commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol 2000 ; 90: 37-47.
21. Spielberger R. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004 ; 351: 2590-2598.